Sutter West Bay Hospitals, doing business as California Pacific Medical Center, operates a not-for-profit academic medical center in California. It offers back pain and spine care services that include lumbar spinal stenosis, herniated disc, cervical spondylosis, spine trauma, spinal tumor, scoliosis, and spine surgery services; cancer care services for brain, breast, colorectal, gynecologic, head and neck, liver, lung and thoracic, pancreas, prostate, pediatric hematology/oncology, and skin cancer; and gastroenterology services, which comprise interventional endoscopy, motility, inflammatory bowel disease, end stage liver disease management, and liver transplantation. The company also provi...
633 Folsom Street
San Francisco, CA 94107
Founded in 1852
California Pacific Medical center Appoints Hamila Kownacki as Chief Operating Officer
Jul 31 15
California Pacific Medical center announced the appointment of Hamila Kownacki, RN, MSHA, as the chief operating officer (COO) at CPMC. Hamila will start in her role effective immediately and will have responsibility for all aspects of operations at CPMC’s four hospital campuses. Kownacki has worked at CPMC and Sutter Health for about 15 years, including the past 7 years as vice president of operations and as chief administrative officer of the Pacific Campus. She has had specific responsibility for many of the adult tertiary and quaternary programs, including organ transplantation, cancer, cardiovascular disease, advanced gastroenterology and diabetes, as well as imaging services.
Insys Therapeutics, Inc. Enters into an Exclusive Licensing Agreement with California Pacific Medical Center on Behalf of its Research Institute
Aug 25 14
Insys Therapeutics Inc. has entered into an exclusive licensing agreement with California Pacific Medical Center on behalf of its Research Institute (CPMCRI) to license CPMCRI's patent rights related to the usage of cannabinoids for the treatment of GBM. In concert with the exclusive licensing agreement, Insys is collaborating with Dr. Sean McAllister at CPMCRI with respect to his pre-clinical research focusing on the ability of CBD to sensitize GBM to current standard of care chemotherapy treatment.